| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Coherus BioSciences will report an earnings per share (EPS) of $-0.32.
Investors in Coherus BioSciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Last quarter the company missed EPS by $0.08, which was followed by a 7.13% drop in the share price the next day.
Here's a look at Coherus BioSciences's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.26 | -0.13 | -0.13 | -0.12 |
| EPS Actual | -0.34 | -0.35 | -0.28 | -0.01 |
| Price Change % | -7.00 | -19.00 | 1.00 | 13.00 |
Shares of Coherus BioSciences were trading at $1.55 as of November 04. Over the last 52-week period, shares are up 89.63%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CHRS
